IFP Advisors Inc Sells 6,784 Shares of Zoetis Inc. $ZTS

IFP Advisors Inc lowered its stake in Zoetis Inc. (NYSE:ZTS) by 68.7% in the third quarter, Holdings Channel.com reports. The institutional investor owned 3,090 shares of the company’s stock after selling 6,784 shares during the quarter. IFP Advisors Inc’s holdings in Zoetis were worth $452,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in ZTS. Brighton Jones LLC raised its stake in shares of Zoetis by 180.4% in the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock valued at $754,000 after acquiring an additional 2,978 shares in the last quarter. Empowered Funds LLC boosted its position in Zoetis by 6.2% during the first quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock worth $1,859,000 after purchasing an additional 657 shares during the period. Intech Investment Management LLC boosted its position in Zoetis by 17.2% during the first quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock worth $1,374,000 after purchasing an additional 1,224 shares during the period. Sivia Capital Partners LLC grew its holdings in Zoetis by 73.8% during the second quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock valued at $522,000 after purchasing an additional 1,422 shares during the last quarter. Finally, Waterloo Capital L.P. acquired a new position in Zoetis during the second quarter valued at approximately $226,000. Institutional investors own 92.80% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on ZTS. William Blair restated an “outperform” rating on shares of Zoetis in a research note on Monday, March 2nd. Morgan Stanley set a $160.00 target price on shares of Zoetis in a research note on Thursday, December 18th. The Goldman Sachs Group upgraded shares of Zoetis to a “buy” rating in a report on Monday, December 15th. Barclays started coverage on shares of Zoetis in a research report on Monday, December 8th. They set an “equal weight” rating and a $136.00 target price for the company. Finally, Piper Sandler reaffirmed a “neutral” rating and issued a $135.00 price target (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. Six analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $152.91.

Zoetis Stock Up 0.6%

Shares of ZTS stock opened at $116.65 on Thursday. Zoetis Inc. has a 12 month low of $113.30 and a 12 month high of $172.23. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71. The firm has a market cap of $49.24 billion, a PE ratio of 19.38, a price-to-earnings-growth ratio of 1.77 and a beta of 0.95. The stock has a 50 day moving average of $123.79 and a 200-day moving average of $129.67.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The business had revenue of $2.39 billion for the quarter, compared to the consensus estimate of $2.36 billion. During the same quarter last year, the company posted $1.40 earnings per share. Zoetis’s quarterly revenue was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, equities analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be given a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 1.8%. The ex-dividend date is Monday, April 20th. Zoetis’s dividend payout ratio (DPR) is currently 35.22%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.